A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK0683 in Patients With Advanced Cancer (0683-008)

NCT00750178 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer, Advanced

Interventions

DRUG: vorinostat (MK0683 )

Sponsor

Merck Sharp & Dohme LLC